Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeTRI: FOLFOXIRI + Bevacizumab in Untreated mCRC
NCT02497157Phase 2Completed
- Sponsor
- Translational Research Center for Medical Innovation
- Start
- May 2015
- Primary completion
- Jun 2019
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, fluorouracil in metastatic colorectal cancer (mCRC), sponsored by Translational Research Center for Medical Innovation. Started May 2015; status: completed.
02
Drugs
bevacizumabirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatinfluorouracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02497157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497157.